Berberine for SIBO: the 2024-2025 evidence update

Berberine has become a fixture of integrative protocols for small intestinal bacterial overgrowth (SIBO), often positioned alongside or as an alternative to rifaximin. The evidence base is smaller than the marketing implies but is no longer purely theoretical. A single comparative trial, several open-label series, and a substantial body of mechanistic work give a clearer picture in 2026 than the field had even three years ago.

What SIBO actually is

SIBO is defined biochemically as elevated bacterial colonization of the small intestine — historically by jejunal aspirate culture (≥10⁵ CFU/mL) and more commonly today by glucose or lactulose hydrogen breath testing. The clinical syndrome includes bloating, postprandial distention, diarrhea or constipation, and nutrient malabsorption. The accepted pharmacologic first line is rifaximin 550 mg three times daily for 10–14 days, with reported eradication rates of 40–70% in published trials [1]. Recurrence is common, which drives interest in adjuncts and alternatives.

The Chedid 2014 comparative trial

The most cited piece of evidence for herbal antimicrobials in SIBO is a 2014 retrospective comparative study from Johns Hopkins. Patients failing standard antibiotic therapy received either a four-week course of an herbal combination including berberine-containing botanicals or rifaximin. Normalization of breath testing was 46% with herbals versus 34% with rifaximin in this non-randomized comparison [2]. This is hypothesis-generating rather than confirmatory — it was retrospective, used a multi-herb formulation rather than berberine alone, and lacked a placebo arm.

What 2024–2025 research has added

Several 2024 and 2025 single-arm and open-label studies in Asia have tested berberine monotherapy (typically 400–500 mg three times daily for 4–6 weeks) in breath-test-confirmed SIBO. Eradication rates of 35–55% have been reported, broadly in the same range as rifaximin in comparable populations [3]. A 2024 randomized trial comparing berberine plus lactulose to rifaximin plus lactulose in IBS-D with SIBO reported non-inferiority for symptom improvement at 8 weeks, though the trial was modestly sized [4]. These data are encouraging but should be read as preliminary; no large, blinded, placebo-controlled trial exists.

Mechanism: why berberine plausibly works

Berberine is a quaternary isoquinoline alkaloid extracted from Berberis species and Coptis chinensis. It has direct antimicrobial activity against many Gram-negative and Gram-positive bacteria at concentrations achievable in the small intestinal lumen. It also modulates intestinal motility through 5-HT3 receptor effects and reduces visceral hypersensitivity in animal models. Crucially, oral berberine has very low systemic bioavailability (under 5%), which means the active concentration stays in the gut — relevant for an intraluminal infection but limiting for any extra-gut indication [5].

Safety and practical use

Berberine is generally well tolerated at 1–1.5 g/day in divided doses. GI side effects (nausea, cramping, constipation, or diarrhea) occur in 10–20% of users. The most important interactions are with CYP3A4 substrates (including cyclosporine, sirolimus, statins, and many cardiovascular medications) — berberine is a moderate CYP3A4 inhibitor, and combination with these drugs can raise their plasma levels. Berberine should not be used in pregnancy or in breastfeeding mothers because of kernicterus risk in newborns through bilirubin displacement [6]. P-glycoprotein inhibition further compounds the interaction profile.

Comparing options honestly

Rifaximin remains the only treatment with regulatory approval, extensive RCT evidence, and a known safety profile for SIBO. Berberine is supported by smaller, less rigorous studies and one comparative effectiveness signal. Cost varies by geography but berberine is typically substantially less expensive than rifaximin in countries where the antibiotic remains brand-priced. The choice between them is therefore not purely scientific — patient access, prior treatment history, and clinician training shape it. Stacking the two is not well studied and is not recommended outside a research setting.

The bottom line

Berberine has a plausible mechanism, encouraging open-label and small randomized data, and one comparative signal against rifaximin. It is not equivalent in evidence weight to standard antibiotic therapy and should not be marketed as such. For patients who have failed or cannot tolerate rifaximin, a 4–6 week trial of berberine 400–500 mg three times daily under clinician supervision is a defensible option. Patients on cardiovascular drug regimens, pregnant women, and nursing mothers should not use it.